Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma

References

• Parrish RK, Palmberg P, Sheu WP. XLT Study Group. A comparison of latanoprost, bimatoprost and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135: 688–703
   PubMed Web of Science ®Google Scholar
• Netland PA, Landry T, Sullivan EK, . Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132: 472–84
   PubMed Web of Science ®Google Scholar
• Barnebey HS, Orengo-Nania S, Flowers BE, . The safety and efficacy of travoprost 0.004 % /timolol 0.5 % fixed-combination ophthalmic solution. Am J Ophthalmol 2005;140: 1–7
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systemic review of the association between dose regimens and medication compliance. Clin Ther 2001;23: 1296–310
   PubMed Web of Science ®Google Scholar
• Robin A, Novack GD, Covert DV, . Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007;144: 533–40
   PubMed Web of Science ®Google Scholar
• Hoy SM, Keam SJ, Keating GM. Travoprost/timolol. Drugs Ageing 2006;23: 587–97
   PubMed Web of Science ®Google Scholar
• Kahook MY, Awadallah N, Noecker RJ. Fixed combination travoprost 0.004 % /timolol 0.5 % for open-angle glaucoma or ocular hypertension. Expert Rev Ophthalmol 2006;1: 25–30
   Google Scholar
• Topuzis F, Melamed S, Danesh-Meyer H, . A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004 % /timolol 0.5 % to once-daily latanoprost 0.005 % /timolol 0.5 % in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007;17: 183–90
   PubMed Web of Science ®Google Scholar
• Schuman JS, Katz GJ, Lewis RA, . Efficacy and safety of a fixed combination of travoprost 0.004 % /timolol 0.5 % ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005;140: 242–50
   PubMed Web of Science ®Google Scholar
• Hughes BA, Bacharach J, Craven R, . A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004 % /timolol 0.5 % ophthalmic solution compared to travoprost 0.004 % ophthalmic solution and timolol 0.5 % dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma 2005;14: 392–9
   PubMed Web of Science ®Google Scholar
• Holló G, Chiselita D, Petkova N, . The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open angle glaucoma. Eur J Ophthalmol 2006;16: 816–23
   PubMed Web of Science ®Google Scholar
• Feldman RM, Tanna AP, Gross RL, . Comparison of ocular hypotensive efficacy of adjunctive brimonidine 0.15 % or brinzolamide 1 % in combination with travoprost 0.004 % . Ophthalmology 2007;114: 1248–54
   PubMed Web of Science ®Google Scholar
• Franks W. the Brinzolamide Study Group. Ocular hypertensive efficacy and safety of brinzolamide ophthalmic suspension 1 % added to travoprost ophthalmic solution 0.004 % therapy in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin 2006;22: 1643–9
   PubMed Web of Science ®Google Scholar
• European Glaucoma Society. Terminology and Guidelines for Glaucoma, 2nd edn. Savona: Dogma S.r.l.:2003
   Google Scholar
• Denis P, Andrew R, Wells D, . A comparison of morning and evening instillation of a combination of travoprost 0.004 % /timolol 0.5 % ophthalmic solution. Eur J Ophthalmol 2006;16: 407–15
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Tsironi S, Vakalis AN, . 24-hour intraocular pressure control with evening versus morning dosed travoprost/timolol fixed combination in primary open-angle and exfoliative glaucoma. Acta Ophthalmol Scand 2008(In press)
   Google Scholar
• Holló G. Use of topical carbonic anhydrase inhibition in glaucoma treatment. In: Pharmacotherapy in GlaucomaIn: Orgül S, Flammer J editors.Bern: Hans Huber Verlag 2000:145–52
   Google Scholar
• Silver LH. the Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 1998;126: 400–8
   PubMed Web of Science ®Google Scholar
• Michaud JE, Friren B. Comparison of topical brinzolamide 1 % and dorzolamide 2 % eye drops given twice daily in addition to timolol 0.5 % in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132: 235–43
   PubMed Web of Science ®Google Scholar
• Silver LH. Brinzolamide Confort Study Group. Ocular comfort of brinzolamide 1 % ophthalmic suspension compared with dorzolamide 2 % ophthalmic solution: results from two multicenter comfort studies. Surv Ophthalmol 2000;44(S2):S141–5
   PubMedGoogle Scholar